Designation of Chlormethine Valchlor as an orphan drug - Actelion Pharmaceuticals Australia Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2015G00468 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

 

DESIGNATION OF Chlormethine VALCHLOR AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate Chlormethine VALCHLOR as an orphan drug on 25 March 2015 for the treatment of cutaneous T cell lymphoma.

The dose form of Chlormethine VALCHLOR for this indication is topical gel.

The sponsor of Chlormethine VALCHLOR is Actelion Pharmaceuticals Australia Pty Ltd.

 

 

(Signed by)

 

Dr Anthony Gill

Delegate of the Secretary

25 March 2015

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.